Richard E. Lowenthal - May 17, 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
May 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:53 PM
Previous filing
Jan 5, 2023
Next filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Gift $0 -1.05M -20.28% $0.00 4.13M May 17, 2023 Direct
transaction SPRY Common Stock Gift $0 +1.05M $0.00 1.05M May 17, 2023 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 F1
transaction SPRY Common Stock Gift $0 -1.05M -24.27% $0.00 3.28M May 17, 2023 By spouse
transaction SPRY Common Stock Gift $0 +1.05M +100% $0.00 2.1M May 17, 2023 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 F1
holding SPRY Common Stock 1.77M May 17, 2023 By Richard E. Lowenthal Charitable Remainder Unitrust Dated January 7, 2020 F2
holding SPRY Common Stock 1.77M May 17, 2023 By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +880K $0.00 880K Jan 2, 2024 Common Stock 880K $5.58 Direct F4
transaction SPRY Stock option (right to buy) Award $0 +300K $0.00 300K Jan 2, 2024 Common Stock 300K $5.58 By spouse F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in a trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
F2 The Reporting Person is trustee of the trust.
F3 The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.